334477-19-9Relevant academic research and scientific papers
Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis- trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor
Di Fabio, Romano,Griffante, Cristiana,Alvaro, Giuseppe,Pentassuglia, Giorgio,Pizzi, Domenica A.,Donati, Daniele,Rossi, Tino,Guercio, Giuseppe,Mattioli, Mario,Cimarosti, Zadeo,Marchioro, Carla,Provera, Stefano,Zonzini, Laura,Montanari, Dino,Melotto, Sergio,Gerrard, Philip A.,Trist, David G.,Ratti, Emiliangelo,Corsi, Mauro
experimental part, p. 3238 - 3247 (2010/04/03)
In an effort to discover novel druglike NK1 receptor antagonists a new series of suitably substituted C-phenylpiperazine derivatives was identified by an appropriate chemical exploration of related N-phenylpiperazine analogues, with the specifi
Synthesis of the NK1 receptor antagonist GW597599. Part 3: Development of a scalable route to a key chirally pure arylpiperazine urea, a happy end
Guercio, Giuseppe,Bacchi, Sergio,Perboni, Alcide,Leroi, Corinne,Tinazzi, Francesco,Bientinesi, Ilaria,Hourdin, Marie,Goodyear, Michael,Curti, Stefano,Provera, Stefano,Cimarosti, Zadeo
scheme or table, p. 1100 - 1110 (2010/04/22)
GW597599 1 is a novel NK-1 antagonist currently under investigation for the treatment of central nervous system disorders and emesis. The initial chemical development synthetic route, derived from the one used by medicinal chemistry, involved several haza
